What is TransMedics Group, Inc.'s non cash interest expense?

TransMedics Group, Inc. (TMDX) reported non cash interest expense of $4.59M in Q1 2026.

TransMedics Group, Inc. TMDX Non Cash Interest Expense

Revenue$173.9M+21.2%

Gross profit$101.2M+14.7%

Operating income$13.3M-51.5%

Net income$7.3M-71.5%

EPS (diluted)$0.20-71.4%

Cash & equivalents$461.7M+48.9%

Total debt$409.9M+505%

Total equity$494.0M+85.5%

Total assets$1.4B+71.3%

Operating cash flow$24.5M+959%

CapEx$36.7M+35.6%

Free cash flow-$12.1M+59.4%

Market cap$2.55B+50.6%

Enterprise value$2.5B+66.0%

P/E14.8×-19.8×

P/S4×+0.5×

Gross margin59.1%-0.4pp

Operating margin14.9%+4.1pp

Net margin27%+17.0pp

FCF margin23.8%—

Return on equity45.2%+22.2pp

Debt / equity0.8×+0.6×

Current ratio6.7×-2.4×

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept tmdx:NonCashInterestExpense.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is TransMedics Group, Inc.'s non cash interest expense?: TransMedics Group, Inc. (TMDX) reported non cash interest expense of $4.59M in Q1 2026.